Regeneron Quarterly Profit Drops 46%
(Reuters) – Regeneron Pharmaceuticals Inc reported an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales. The company reported net income of $1.20 billion, or $10.50 per share, in the quarter ended Dec. 31,…